Bris­tol-My­ers Squib­b's Op­di­vo/Yer­voy com­bo scores col­orec­tal can­cer OK; For­mer Ake­bia, Mer­ri­mack staffers found guilty

→ Bol­stered by pri­or­i­ty re­view and a break­through ther­a­py des­ig­na­tion, Bris­tol-My­ers Squibb’s Op­di­vo/Yer­voy has been ap­proved for a sub­set of col­orec­tal can­cer pa­tients who’ve run …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER